FACULTY
Ursula A. Matulonis, MD
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Professor of Medicine
Harvard Medical School
Co-PI, Ovarian cancer SPORE grant
Co-leader, GYN program
Dana-Farber/Harvard Cancer Center
Boston, MA
Bradley J. Monk, MD, FACS, FACOG
Florida Cancer Specialists and Research Institute
Medical Director Late-Phase Clinical Research
Vice President and Member Board of Directors GOG-Foundation
West Palm Beach, FL
PROGRAM OVERVIEW
Antibody-drug conjugates (ADCs) are an important advancement in the treatment of cancer. We are pleased to present an informative enduring activity designed to equip you with information and skills needed to optimally use ADCs for your patients with advanced gynecologic cancers. The format of this program includes didactic presentations, case presentations, and discussion sessions, along with audience response technology. Renowned experts will review the latest evidence and clinical guidelines related to ADCs for women’s cancers and share their perspectives and guidance on incorporating these agents into practice, including individualized treatment planning and multidisciplinary toxicity monitoring and management.
TARGET AUDIENCE
This activity is designed to meet the educational needs of medical, gynecologic, surgical, and radiation oncologists; advanced healthcare practitioners; nurses; and other healthcare professionals involved in the treatment of patients with gynecologic malignancies.
LEARNING OBJECTIVES
- Describe the mechanisms of action of antibody-drug conjugates (ADCs) and the rationale for their use in gynecologic cancers
- Develop personalized strategies for incorporating ADCs into the treatment of patients with advanced gynecologic cancers
- Assess and manage adverse events associated with administration of ADCs in gynecologic cancers
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this enduring activity for a maximum of 1.50 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Ursula A. Matulonis, MD | Consulting fees: Merck Scientific Advisory Board: AbbVie, Allarity, Eisai, GSK, Immunogen, NextCure, Novartis, Profound Bio, the Ovarian Cancer Research Alliance, Tango Therapeutics Data Safety Monitoring Board: Mural Oncology and Symphogen |
| Bradley J. Monk, MD, FACS, FACOG | Speaker: AstraZenca, DSI, Easai, GSK, Immiogen/AbbVie, Merck Consulting fees: AstraZeneca, BioNtech, Corcept, DSI, Eisai, Eli Lilly, Genmab/Seagen/Pfizer, GOG Foundation, GSK, Immunogen/AbbVie, Incyte, Karyopharm, Merck, Mersana, Mural/Alkermes, Myriad, Natera, Novartis, Novocure, OncoC4, Panavance Pharma & ProfoundBio/Genmab, Regeneron, Roche/Genentech, Sutro, Tubulis, Verastem, Zentalis, Zymeworks |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer-reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, MBA, CEO of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, SVP, Operations for Med Learning Group, has nothing to disclose.
- Briana Hefele, PA-C, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC, has nothing to disclose.
- Kim Farina, PhD, Medical Director for Med Learning Group, has nothing to disclose.
- Tom Bregartner, MBA, VP of Outcomes and Accreditation for Med Learning Group, has nothing to disclose.
- Aimee Meissner, Outcomes and Accreditation Coordinator for Med Learning Group, has nothing to disclose.
- Felecia Beachum, Sr. Program Manager for Med Learning Group, has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science based. This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at http://medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: May 05, 2025
EXPIRATION DATE: May 05, 2026
Copyright © 2025 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
